Metabolic activity assessment by 18 F‐fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium‐90 transarterial radioembolization-Reference-Cited by-同舟云学术

Metabolic activity assessment by 18 F‐fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium‐90 transarterial radioembolization

Published:2021-01-31 Issue:6 Volume:36 Page:1679-1684
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Kim Do Young¹^ORCID,Lee Hye Won¹^ORCID,Kang Wonseok²,Kim Gyoung Min³,Won Jong Yun³,Yun Mijin⁴

Affiliation:

1. Department of Internal Medicine Yonsei University College of Medicine Seoul South Korea

2. Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

3. Department of Radiology Yonsei University College of Medicine Seoul South Korea

4. Department of Nuclear Medicine Yonsei University College of Medicine Seoul South Korea

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15357

Reference28 articles.

1. Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months

2. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

4. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

5. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization;Clinical Nuclear Medicine;2022-04-04